智通财经网·2025-12-15 14:27Core Viewpoint - WuXi AppTec (02359) has completed the sale of all shares of Kande Hongyi and Jinshi Pharmaceutical to Hillhouse Capital, receiving the first payment of RMB 1.54 billion, with the transaction now finalized [1] Group 1: Transaction Details - WuXi AppTec has received the first installment of the transfer price amounting to RMB 1.54 billion as per the equity transfer agreement [1] - The prerequisites for the transaction have been met, and the equity transfer has been completed, meaning Kande Hongyi and Jinshi Pharmaceutical will no longer be included in the company's consolidated financial statements [1] - The parties involved will proceed with the necessary procedures for the equity change registration, expected to be completed by December 31, 2025 [1] Group 2: Financial Impact - The transaction is expected to generate an after-tax net profit of approximately RMB 960 million, which represents over 10% of the company's latest audited net profit attributable to shareholders for the fiscal year 2024 [1] - The company will account for the investment income according to Chinese Accounting Standards and International Financial Reporting Standards, with the specific impact to be confirmed by the annual audit [1]